Recombinant Human PADI4 Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Peptidyl-arginine deiminase-4 (PADI4) is a member of the peptide arginine deiminase family, which can catalyze the conversion of peptidyl arginine to citrulline in the presence of calcium ions (1). The process leads to the post-translational modification of proteins. Five isoforms of this family are present in vertebrates: PADI1, 2, 3, 4, and 6. PADI4 is predominantly expressed in blood lymphocytes and has been suggested to play a role in inflammation and the immune response. High expression of PADI4 has been detected in synovial tissues of rheumatoid arthritis (RA) patients producing autoantibodies that recognize citrulline containing proteins, and the enzyme is also present in monocytes, macrophages, eosinophils and neutrophils of the affected tissue (2). Thus, PADI4 is believed to play a causative role in RA. It also may be involved with transcription and apotosis by antagonizing the methylation of histones H2A, H3, and H4 via deimination which represses hormone (estrogen)-target transcription and interrupts cell apoptosis (3). It is a target gene of p53 in DNA damage response to induce protein citrullination (4). Its high expression in a variety of malignant tumors compared to normal tissues and benign tumors and its detection in the plasma of patients with malignant tumors makes it a potential tumor marker (5). It is also implicated in demyelinating diseases such as multiple sclerosis because of increased expression of PADI2 and PADI4 in myelin isolated from patients with MS (6).

Array 6660-AD

• PADI4 Antibodies
• PADI4 Lysate
• PADI4 Proteins
• PADI4 Proteins and Enzyme